Xilio Therapeutics, Inc.
General ticker "XLO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $47.2M (TTM average)
Xilio Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -1.4%.
Estimated limits based on current volatility of 2.4%: low 0.71$, high 0.74$
Factors to consider:
- Total employees count: 64 (-12.3%) as of 2024
- Top business risk factors: Economic downturns and volatility, Manufacturing risks, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.73$, 1.86$]
- 2025-12-31 to 2026-12-31 estimated range: [0.67$, 1.70$]
Short-term XLO quotes
Long-term XLO plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $6.34MM |
| Operating Expenses | $89.15MM | $79.13MM | $66.93MM |
| Operating Income | $-89.15MM | $-79.13MM | $-60.58MM |
| Non-Operating Income | $0.93MM | $2.73MM | $2.34MM |
| R&D Expense | $59.20MM | $52.14MM | $41.21MM |
| Income(Loss) | $-88.22MM | $-76.40MM | $-58.24MM |
| Profit(Loss)* | $-88.22MM | $-76.40MM | $-58.24MM |
| Stockholders Equity | $105.65MM | $36.83MM | $17.60MM |
| Assets | $139.16MM | $60.93MM | $71.08MM |
| Operating Cash Flow | $-75.72MM | $-68.62MM | $-18.38MM |
| Capital expenditure | $1.87MM | $0.49MM | $0.04MM |
| Investing Cash Flow | $-1.87MM | $-0.49MM | $-0.04MM |
| Financing Cash Flow | $-0.07MM | $-6.55MM | $29.20MM |
| Earnings Per Share** | $-3.22 | $-2.78 | $-1.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.